Trial Profile
A Multi-national Trial Evaluating Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Patients With Haemophilia A
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jan 2022
Price :
$35
*
At a glance
- Drugs Turoctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms PATHFINDER 2
- Sponsors Novo Nordisk
- 01 Jan 2022 Results of post-hoc analysis of two studies (pathfinder 2 and pathfinder 5) assessing long-term efficacy and pharmacokinetic outcomes with fixed-dose N8-GP prophylaxis, published in the Haemophilia.
- 01 Jan 2022 Post hoc analysis was performed by applying datamining techniques retrospectively to the final results of the pathfinder 2 and 3 clinical trials and analysing the resulting data descriptively; results published in the Haemophilia
- 19 Nov 2020 A pharmacodynamic pharmacokinetic decision model was developed to predict comparative bleed outcomes of adults and adolescents with severe haemophilia A receiving treatment with EHL FVIIIs, capturing differences in cumulative bleeding episodes and breakthrough bleed resolution and resource costs; results presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research